Chardan Reiterates Sell On Esperion Therapeutics, Sees At Least 6 Reasons To Beware

In a report published Wednesday, Chardan Capital Markets analyst Gbola Amusa maintained a Sell rating on Esperion Therapeutics Inc ESPR, while raising the price target from $50 to $55, saying that the FDA had removed the 240 mg partial clinical hold on the company’s Phase IIb cholesterol-lowering drug, ETC-1002, “allowing ETC-1002 to be used at doses above 240 mg in clinical studies.”

In the report Chardan Capital Markets noted the concerns surrounding Esperion Therapeutics:

  1. “ETC-1002 works upstream of statins, and its efficacy can likely be replicated by uptitrating lower-dose to higher-dose statins…
  2. ETC-1002 is an old (and slow-to-develop) asset, and pharma companies have chosen not to develop similar-mechanism compounds…
  3. Believing in ETC-1002 safety is a leap of faith at this point…
  4. We cannot find a logical place to use ETC-1002, even if it is approved, given ETC-1002's modest LDL-lowering efficacy and given its add-on data include use only with low-dose statins…
  5. Post the recent FDA panels, FDA commentary suggests the statin intolerance market is 8% of where many thought…
  6. The recent anti-PCK9 FDA panels (and Dr. Califf's online comments) to us clearly show an expert bias and an FDA bias towards drugs proving utility beyond simple LDL-lowering…”

Analyst Gbola Amusa continues to believe that any impediments in study ETC-1002-014, scheduled for July, or the FDA end-of-phase-II process, scheduled for 2H15, could result in “significant share price downside.”

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationAnalyst RatingsChardan Capital Markets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!